(Q33404570)

26 July 2017

title

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma (English)

1 reference

26 July 2017

1 reference

22

Dietger Niederwieser

1 reference

26 July 2017

Wolfram Pönisch

1

1 reference

26 July 2017

Malvina Bourgeois

2

1 reference

26 July 2017

Barbara Moll

3

1 reference

26 July 2017

Simone Heyn

4

1 reference

26 July 2017

Nadja Jäkel

5

1 reference

26 July 2017

Ina Wagner

6

1 reference

26 July 2017

Robert Rohrberg

7

1 reference

26 July 2017

Hans-Jürgen Hurtz

8

1 reference

26 July 2017

Marion Schmalfeld

9

1 reference

26 July 2017

Michael Aßmann

10

1 reference

26 July 2017

Thomas Edelmann

11

1 reference

26 July 2017

Martin Mohren

12

1 reference

26 July 2017

Franz Albert Hoffmann

13

1 reference

26 July 2017

Cornelia Becker

14

1 reference

26 July 2017

Andreas Schwarzer

15

1 reference

26 July 2017

Uta Schönfelder

16

1 reference

26 July 2017

Thomas Zehrfeld

17

1 reference

26 July 2017

Gerald Hensel

18

1 reference

26 July 2017

Kerstin Löschcke

19

1 reference

26 July 2017

Rainer Krahl

20

1 reference

26 July 2017

Haifa Al Ali

21

1 reference

26 July 2017

publication date

25 November 2012

1 reference

Journal of Cancer Research and Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

139

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

499-508

1 reference

The treatment of multiple myeloma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1339-3

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

21 January 2018

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

1 reference

12 December 2020

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

1 reference

12 December 2020

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy

1 reference

12 December 2020

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

12 December 2020

10.1007/S00432-012-1339-3

Identifiers

DOI

1 reference

26 July 2017

1 reference